Literature DB >> 32311027

Digenic Heterozygous Mutations in SLC34A3 and SLC34A1 Cause Dominant Hypophosphatemic Rickets with Hypercalciuria.

Rebecca J Gordon1,2, Dong Li3, Daniel Doyle4, Joshua Zaritsky5, Michael A Levine2.   

Abstract

CONTEXT: Hypophosphatemia and metabolic bone disease are associated with hereditary hypophosphatemic rickets with hypercalciuria (HHRH) due to biallelic mutations of SLC34A3 encoding the NPT2C sodium-phosphate cotransporter and nephrolithiasis/osteoporosis, hypophosphatemic 1 (NPHLOP1) due to monoallelic mutations in SLC34A1 encoding the NPT2A sodium-phosphate cotransporter.
OBJECTIVE: To identify a genetic cause of apparent dominant transmission of HHRH. DESIGN AND
SETTING: Retrospective and prospective analysis of clinical and molecular characteristics of patients studied in 2 academic medical centers.
METHODS: We recruited 4 affected and 3 unaffected members of a 4-generation family in which the proband presented with apparent HHRH. We performed clinical examinations, biochemical and radiological analyses, and molecular studies of genomic DNA.
RESULTS: The proband and her affected sister and mother carried pathogenic heterozygous mutations in 2 related genes, SLC34A1 (exon 13, c.1535G>A; p.R512H) and SLC34A3 (exon 13, c.1561dupC; L521Pfs*72). The proband and her affected sister inherited both gene mutations from their mother, while their clinically less affected brother, father, and paternal grandmother carried only the SLC34A3 mutation. Renal phosphate-wasting exhibited both a gene dosage-effect and an age-dependent attenuation of severity.
CONCLUSIONS: We describe a kindred with autosomal dominant hypophosphatemic rickets in which whole exome analysis identified digenic heterozygous mutations in SLC34A1 and SLC34A3. Subjects with both mutations were more severely affected than subjects carrying only one mutation. These findings highlight the challenges of assigning causality to plausible genetic variants in the next generation sequencing era. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 SLC34Azzm321990 ; zzm321990 SLC34A1zzm321990 ; digenic; hypercalciuria; hypophosphatemia; rickets

Mesh:

Substances:

Year:  2020        PMID: 32311027      PMCID: PMC7448300          DOI: 10.1210/clinem/dgaa217

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  47 in total

1.  Closing the gaps in pediatric laboratory reference intervals: a CALIPER database of 40 biochemical markers in a healthy and multiethnic population of children.

Authors:  David A Colantonio; Lianna Kyriakopoulou; Man Khun Chan; Caitlin H Daly; Davor Brinc; Allison A Venner; Maria D Pasic; David Armbruster; Khosrow Adeli
Journal:  Clin Chem       Date:  2012-02-27       Impact factor: 8.327

2.  Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities.

Authors:  L Beck; A C Karaplis; N Amizuka; A S Hewson; H Ozawa; H S Tenenhouse
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

3.  Digenic Heterozygous Mutations in SLC34A3 and SLC34A1 Cause Dominant Hypophosphatemic Rickets with Hypercalciuria.

Authors:  Rebecca J Gordon; Dong Li; Daniel Doyle; Joshua Zaritsky; Michael A Levine
Journal:  J Clin Endocrinol Metab       Date:  2020-07-01       Impact factor: 5.958

4.  Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3.

Authors:  Bettina Lorenz-Depiereux; Anna Benet-Pages; Gertrud Eckstein; Yardena Tenenbaum-Rakover; Janine Wagenstaller; Dov Tiosano; Ruth Gershoni-Baruch; Norbert Albers; Peter Lichtner; Dirk Schnabel; Ze'ev Hochberg; Tim M Strom
Journal:  Am J Hum Genet       Date:  2005-12-09       Impact factor: 11.025

5.  NHERF1 mutations and responsiveness of renal parathyroid hormone.

Authors:  Zoubida Karim; Bénédicte Gérard; Naziha Bakouh; Rohia Alili; Christine Leroy; Laurent Beck; Caroline Silve; Gabrielle Planelles; Pablo Urena-Torres; Bernard Grandchamp; Gérard Friedlander; Dominique Prié
Journal:  N Engl J Med       Date:  2008-09-11       Impact factor: 91.245

6.  Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter.

Authors:  Dominique Prié; Virginie Huart; Naziha Bakouh; Gabrielle Planelles; Olivier Dellis; Bénédicte Gérard; Philippe Hulin; François Benqué-Blanchet; Caroline Silve; Bernard Grandchamp; Gérard Friedlander
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

Review 7.  The molecular mechanism of SLC34 proteins: insights from two decades of transport assays and structure-function studies.

Authors:  Ian C Forster
Journal:  Pflugers Arch       Date:  2018-09-22       Impact factor: 3.657

8.  Genetic determination of height-mediated mate choice.

Authors:  Albert Tenesa; Konrad Rawlik; Pau Navarro; Oriol Canela-Xandri
Journal:  Genome Biol       Date:  2016-01-19       Impact factor: 13.583

9.  SLC34A3 Intronic Deletion in an Iranian Kindred with Hereditary Hypophosphatemic Rickets with Hypercalciuria

Authors:  Shirin Hasani-Ranjbar; Hanieh-Sadat Ejtahed; Mahsa M. Amoli; Fatemeh Bitarafan; Mostafa Qorbani; Akbar Soltani; Bahareh Yarjoo
Journal:  J Clin Res Pediatr Endocrinol       Date:  2018-05-29

10.  Fast and accurate short read alignment with Burrows-Wheeler transform.

Authors:  Heng Li; Richard Durbin
Journal:  Bioinformatics       Date:  2009-05-18       Impact factor: 6.937

View more
  7 in total

1.  Digenic Heterozygous Mutations in SLC34A3 and SLC34A1 Cause Dominant Hypophosphatemic Rickets with Hypercalciuria.

Authors:  Rebecca J Gordon; Dong Li; Daniel Doyle; Joshua Zaritsky; Michael A Levine
Journal:  J Clin Endocrinol Metab       Date:  2020-07-01       Impact factor: 5.958

Review 2.  Noncanonical Sequences Involving NHERF1 Interaction with NPT2A Govern Hormone-Regulated Phosphate Transport: Binding Outside the Box.

Authors:  Tatyana Mamonova; Peter A Friedman
Journal:  Int J Mol Sci       Date:  2021-01-22       Impact factor: 5.923

3.  Hypercalciuria in Postmenopausal Women With Reduced Bone Mineral Density Is Associated With Different Mineral Metabolic Profiles: Effects of Treatment With Thiazides and Anti-resorptives.

Authors:  Federico Nicoli; Giorgia Dito; Gregorio Guabello; Matteo Longhi; Sabrina Corbetta
Journal:  Front Med (Lausanne)       Date:  2021-12-15

Review 4.  The Genetics of Inherited Cholestatic Disorders in Neonates and Infants: Evolving Challenges.

Authors:  Rebecca Jeyaraj; Kirsten McKay Bounford; Nicola Ruth; Carla Lloyd; Fiona MacDonald; Christian J Hendriksz; Ulrich Baumann; Paul Gissen; Deirdre Kelly
Journal:  Genes (Basel)       Date:  2021-11-21       Impact factor: 4.096

5.  Comprehensive Genetic Analysis Reveals Complexity of Monogenic Urinary Stone Disease.

Authors:  Andrea G Cogal; Jennifer Arroyo; Ronak Jagdeep Shah; Kalina J Reese; Brenna N Walton; Laura M Reynolds; Gabrielle N Kennedy; Barbara M Seide; Sarah R Senum; Michelle Baum; Stephen B Erickson; Sujatha Jagadeesh; Neveen A Soliman; David S Goldfarb; Lada Beara-Lasic; Vidar O Edvardsson; Runolfur Palsson; Dawn S Milliner; David J Sas; John C Lieske; Peter C Harris
Journal:  Kidney Int Rep       Date:  2021-09-08

Review 6.  The Complexities of Organ Crosstalk in Phosphate Homeostasis: Time to Put Phosphate Sensing Back in the Limelight.

Authors:  Lucile Figueres; Sarah Beck-Cormier; Laurent Beck; Joanne Marks
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

7.  Overlapping Phenotypes Associated With CYP24A1, SLC34A1, and SLC34A3 Mutations: A Cohort Study of Patients With Hypersensitivity to Vitamin D.

Authors:  Arnaud Molin; Sandrine Lemoine; Martin Kaufmann; Pierre Breton; Marie Nowoczyn; Céline Ballandonne; Nadia Coudray; Hervé Mittre; Nicolas Richard; Amélie Ryckwaert; Alinoe Lavillaureix; Glenville Jones; Justine Bacchetta; Marie-Laure Kottler
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-13       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.